192 related articles for article (PubMed ID: 29885068)
1. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
[TBL] [Abstract][Full Text] [Related]
3. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
[TBL] [Abstract][Full Text] [Related]
4. First Human Study of the Investigational Sedative and Anesthetic Drug AZD3043: A Dose-Escalation Trial to Assess the Safety, Pharmacokinetics, and Efficacy of a 30-Minute Infusion in Healthy Male Volunteers.
Kalman S; Koch P; Ahlén K; Kanes SJ; Barassin S; Björnsson MA; Norberg Å
Anesth Analg; 2015 Oct; 121(4):885-893. PubMed ID: 26111262
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
8. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
François B; Lambden S; Garaud JJ; Derive M; Grouin JM; Asfar P; Darreau C; Mira JP; Quenot JP; Lemarié J; Mercier E; Lacherade JC; Vinsonneau C; Fivez T; Helms J; Badie J; Levy M; Cuvier V; Salcedo-Magguilli M; Laszlo-Pouvreau AL; Laterre PF; Gibot S;
EClinicalMedicine; 2023 Jun; 60():102013. PubMed ID: 37350989
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
11. A Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers.
Norberg Å; Koch P; Kanes SJ; Björnsson MA; Barassin S; Ahlén K; Kalman S
Anesth Analg; 2015 Oct; 121(4):894-903. PubMed ID: 26097986
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study.
Zhao Q; Liu H; Wang Z; Wang T; Cui C; Wang H; Li L; Zhong W; Jiang J; Dong K; Chen S; Jin C; Hu P
Adv Ther; 2023 Jul; 40(7):3186-3198. PubMed ID: 37233875
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
16. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
17. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.
Cass RT; Brooks CD; Havrilla NA; Tack KJ; Borin MT; Young D; Bruss JB
Antimicrob Agents Chemother; 2011 Dec; 55(12):5874-80. PubMed ID: 21911572
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
